A phase I dose-escalation study of clofarabine in combination with fractionated gemtuzumab ozogamicin in patients with refractory or relapsed acute myeloid leukemia

References

• Craddock C, Tauro S, Moss P, . Biology and management of relapsed acute myeloid leukaemia. Br J Haematol 2005 129:18–34.
   PubMed Web of Science ®Google Scholar
• Duval M, Klein JP, He W, . Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 2010;28:3730–3738.
   PubMed Web of Science ®Google Scholar
• Grigg AP, Szer J, Beresford J, . Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemia. Br J Haematol 1999;107:409–418.
   PubMed Web of Science ®Google Scholar
• Walter RB, Gooley TA, Wood BL, . Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol 2011;29:1190–1197.
   PubMed Web of Science ®Google Scholar
• Advani R, Saba HI, Tallman MS, . Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood 1999 93:787–795.
   PubMed Web of Science ®Google Scholar
• Brown RA, Herzig RH, Wolff SN, . High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy. Blood 1990;76:473–479.
   PubMed Web of Science ®Google Scholar
• Herzig RH, Lazarus HM, Wolff SN, . High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia. J Clin Oncol 1985;3:992–997.
   PubMed Web of Science ®Google Scholar
• Ho AD, Lipp T, Ehninger G, . Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia—an active and well-tolerated regimen. J Clin Oncol 1988;6:213–217.
   PubMed Web of Science ®Google Scholar
• Pastore D, Specchia G, Carluccio P, . FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience. Ann Hematol 2003;82:231–235.
   PubMed Web of Science ®Google Scholar
• Breems DA, Van Putten WL, Huijgens PC, . Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 2005;23:1969–1978.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Russell NH, Kell J, . European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol 2010;28:2389–2395.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Erba HP, Claxton D, . Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 2010;28:549–555.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Gandhi V, Cortes J, . Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003;102:2379–2386.
   PubMed Web of Science ®Google Scholar
• Becker PS, Kantarjian H, Appelbaum FR, . Multivariate analysis of response and survival after treatment with clofarabine, cytarabine and G-CSF priming (GCLAC) in relapsed/refractory acute myeloid leukemia (AML): comparison with prior experience using fludarabine and cytarabine combination regimens. Blood 2010;116(Suppl. 1): Abstract 1065.
   Google Scholar
• Faderl S, Ravandi F, Huang X, . A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008;112:1638–1645.
   PubMed Web of Science ®Google Scholar
• Hamann PR, Hinman LM, Hollander I, . Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem 2002;13:47–58.
   PubMed Web of Science ®Google Scholar
• Rajvanshi P, Shulman HM, Sievers EL, . Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood 2002;99:2310–2314.
   PubMed Web of Science ®Google Scholar
• Larson RA, Sievers EL, Stadtmauer EA, . Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005;104:1442–1452.
   PubMed Web of Science ®Google Scholar
• McKoy JM, Angelotta C, Bennett CL, . Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res 2007;31:599–604.
   PubMed Web of Science ®Google Scholar
• Taksin AL, Legrand O, Raffoux E, . High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the ALFA group. Leukemia 2007;21:66–71.
   PubMed Web of Science ®Google Scholar
• Nand S, Godwin J, Smith S, . Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. Leuk Lymphoma 2008;49:2141–2147.
   PubMed Web of Science ®Google Scholar
• Middeldorf I, Galm O, Osieka R, . Sequence of administration and methylation of SOCS3 may govern response to gemtuzumab ozogamicin in combination with conventional chemotherapy in patients with refractory or relapsed acute myelogenous leukemia (AML). Am J Hematol 2010;85:477–481.
   PubMed Web of Science ®Google Scholar
• Stone RM, Moser B, Sanford B, . High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902. Leuk Res 2011;35:329–333.
   PubMed Web of Science ®Google Scholar
• Bonate PL, Arthaud L, Cantrell WR Jr, . Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov 2006;5:855–863.
   PubMed Web of Science ®Google Scholar
• Ivanova A, Flournoy N, Chung Y. Cumulative cohort design for dose-finding. J Stat Plan Inference 2007;137:2316–2317.
   Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kopecky KJ, . Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642–4649.
   PubMed Web of Science ®Google Scholar
• Estey E, Kornblau S, Pierce S, . A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia. Blood 1996;88:756.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Hills RK, Moorman AV, . Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010;116:354–365.
   PubMed Web of Science ®Google Scholar
• Capizzi RL, Davis R, Powell B, . Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia—a Cancer and Leukemia Group B Study. J Clin Oncol 1988;6:499–508.
   PubMed Web of Science ®Google Scholar
• Chevallier P, Prebet T, Turlure P, . Prior treatment with gemtuzumab ozogamicin and the risk of veno-occlusive disease after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 2010;45:165–170.
   PubMed Web of Science ®Google Scholar
• Bornhauser M, Illmer T, Oelschlaegel U, . Gemtuzumab ozogamicin as part of reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in patients with relapsed acute myeloid leukemia. Clin Cancer Res 2008;14:5585–5593.
   PubMed Web of Science ®Google Scholar
• de Lima M, Champlin RE, Thall PF, . Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia 2008;22:258–264.
   PubMed Web of Science ®Google Scholar
• Wadleigh M, Richardson PG, Zahrieh D, . Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003;102:1578–1582.
   PubMed Web of Science ®Google Scholar
• Attal M, Huguet F, Rubie H, . Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood 1992;79:2834–2840.
   PubMed Web of Science ®Google Scholar
• Versluys B, Bhattacharaya R, Steward C, . Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure. Blood 2004;103:1968.
   PubMed Web of Science ®Google Scholar
• van der Velden VH, Boeckx N, Jedema I, . High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients. Leukemia 2004;18:983–988.
   PubMed Web of Science ®Google Scholar
• Jeha S, Gandhi V, Chan KW, . Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2004;103:784–789.
   PubMed Web of Science ®Google Scholar
• Jeha S, Gaynon PS, Razzouk BI, . Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 2006;24:1917–1923.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Gandhi V, Kozuch P, . Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003;21:1167–1173.
   PubMed Web of Science ®Google Scholar
• Borthakur G, Garcia-Manero G, Estrov Z, . Phase 2 study of decitabine and gemtuzumab ozogamicin in acute myelogenous leukemia and high-risk myelodysplastic syndrome - outcome in previously untreated patients. Blood 2009;114(Suppl. 1):Abstract 1053.
   Google Scholar
• Burnett AK, Hills RK, Milligan D, . Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 2011;29:369–377.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Pfizer voluntarily withdraws cancer treatment Mylotarg from US market. Washington, DC: FDA; 2010.
   Google Scholar
• Clarke WT, Marks PW. Gemtuzumab ozogamicin: is there room for salvage? Blood 2010;116:2618–2619.
   PubMed Web of Science ®Google Scholar